Annovis Bio Inc (NYSE: ANVS ) received notice from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed.
The FDA accepted the final protocol and the clinical development plan and approved using the company's new large-scale batch of good manufacturing practice material.
The agency found the chronic toxicology in rats and dogs safe and adequate ... Full story available on Benzinga.com